Analysts Offer Insights on Healthcare Companies: Arcellx Inc (ACLX) and Apellis Pharmaceuticals (APLS)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Arcellx Inc (ACLX – Research Report) and Apellis Pharmaceuticals (APLS – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Arcellx Inc (ACLX)
Arcellx Inc received a Hold rating from TD Cowen analyst Tyler Van Buren today. The company’s shares closed last Friday at $113.79.
According to TipRanks.com, Buren is a 5-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Arcellx Inc with a $112.67 average price target, implying a -1.2% downside from current levels. In a report issued on February 27, TipRanks – OpenAI also upgraded the stock to Hold with a $122.00 price target.
See today’s best-performing stocks on TipRanks >>
Apellis Pharmaceuticals (APLS)
In a report released today, Lachlan Hanbury Brown from William Blair maintained a Buy rating on Apellis Pharmaceuticals. The company’s shares closed last Friday at $20.96.
According to TipRanks.com, Brown is a 4-star analyst with an average return of
Apellis Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $31.15, a 46.2% upside from current levels. In a report issued on February 24, Needham also maintained a Buy rating on the stock with a $28.00 price target.
